Immunization MMWRs

March 2021

• 

  Oliver SE, Gargano JW, Scobie H, Wallace M, Hadler SC, Leung J, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021 MMWR. 2021;70(early release).
  The Janssen COVID-19 vaccine has high efficacy against COVID-19–associated hospitalization and death…

February 2021

• 

  Rinott E, Youngster I, Lewis YE. Reduction in COVID-19 Patients Requiring Mechanical Ventilation Following Implementation of a National COVID-19 Vaccination Program — Israel, December 2020–February 2021 MMWR. 2021;70(early release).
  These findings provide preliminary evidence of the effectiveness of vaccines in preventing severe cases of COVID-19 at the national level in Israel…

• 

  Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, Nair N, et al. First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021 MMWR. 2021;70(8);283-8.
  Monitoring, conducted as part of the U.S. vaccination program, indicates reassuring safety profiles for COVID-19 vaccines…

• 

  Batdorf SJ, Hofmeister MG, Surtees TC, Thomasson ED, McBee SM, Pauly NJ. Estimated Medicaid Costs Associated with Hepatitis A During an Outbreak — West Virginia, 2018–2019 MMWR. 2021;70(8);269-72.
  the results from this study highlight the potential financial cost jurisdictions might incur when ACIP recommendations for hepatitis A vaccination, especially among persons who use illicit drugs, are not followed…

• 

  Hong K, Zhou F, Tsai Y, Jatlaoui TC, Acosta AM, Dooling KL, et al. Decline in Receipt of Vaccines by Medicare Beneficiaries During the COVID-19 Pandemic — United States, 2020 MMWR. 2021;70(7);245–9.
  Vaccination providers should emphasize the importance of routine adult vaccination to their patients and ensure the safe provision of vaccines to protect older adults from vaccine-preventable diseases during the ongoing COVID-19 pandemic…

• 

  Nguyen KH, Srivastav A, Razzaghi H, Williams W, Lindley MC, Jorgensen C, et al. COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination — United States, September and December 2020 MMWR. 2021;70(6);217–22.
  Ensuring high and equitable vaccination coverage among all populations, including by addressing reasons for not intending to receive vaccination, is critical to prevent the spread of COVID-19 and bring an end to the pandemic…

• 

  Freedman MS, Ault K, Bernstein H. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2021 MMWR. 2021;70(6);193-6.
  The 2021 adult immunization schedule summarizes ACIP recommendations, including several changes from the 2020 immunization schedule on the cover page, two tables, and accompanying notes found on the CDC immunization schedule website…

• 

  Wodi AP, Ault K, Hunter P, McNally V, Szilagyi PG, Bernstein H. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2021 MMWR. 2021;70(6);189-92.
  The 2021 child and adolescent immunization schedule summarizes ACIP recommendations, including several changes from the 2020 immunization schedule on the cover page, two tables, and notes found on the CDC immunization schedule website…

• 

  Gharpure R, Guo A, Bishnoi CK, Patel U, Gifford D, Tippins A, et al. Early COVID-19 First-Dose Vaccination Coverage Among Residents and Staff Members of Skilled Nursing Facilities Participating in the Pharmacy Partnership for Long-Term Care Program — United States, December 2020–January 2021 MMWR. 2021;70(5);178-82.
  Barriers to SNF staff member vaccination need to be overcome with continued development and implementation of focused communication and outreach strategies to improve vaccination coverage…

• 

  Painter EM, Ussery EN, Patel A, PharmD, Hughes MM, Zell ER, MStat, Moulia DL, et al. Demographic Characteristics of Persons Vaccinated During the First Month of the COVID-19 Vaccination Program — United States, December 14, 2020–January 14, 2021 MMWR. 2021;70(5);174-7.
  As the vaccination program expands, it is critical to ensure efficient and equitable administration to persons in each successive vaccine priority category, especially those at highest risk for infection and severe health outcomes…

January 2021

• 

  CDC COVID-19 Response Team; Food and Drug Administration. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021 MMWR. 2021;70(4);125-9.
  This report summarizes the clinical and epidemiologic characteristics of case reports of allergic reactions, including anaphylaxis and nonanaphylaxis allergic reactions, after receipt of the first dose of Moderna COVID-19 vaccine during December 21, 2020–January 10, 2021, in the United States. CDC has issued updated interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States and interim considerations for preparing for the potential management of anaphylaxis…

• 

  Seither R, McGill MT, Kriss JL, Mellerson JL, Loretan C, Driver K, et al. Vaccination Coverage with Selected Vaccines and Exemption Rates Among Children in Kindergarten — United States, 2019–20 School Year MMWR. 2021;70(3);75–82.
  This report provides data on overall national and median vaccination coverage for the state-required number of doses of DTaP, MMR, and varicella vaccine…

• 

  Choi MJ, Cossaboom CM, Whitesell AN, Dyal JW, Joyce A, Morgan RL, et al. Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020 MMWR. 2021;70(RR-1);1-12.
  This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the rVSVΔG-ZEBOV-GP Ebola vaccine (Ervebo) in the United States…

• 

  CDC COVID-19 Response Team; Food and Drug Administration. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020 MMWR. 2021;70(2);46–51.
  This report summarizes the clinical and epidemiologic characteristics of case reports of allergic reactions, including anaphylaxis and nonanaphylaxis allergic reactions, after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine during December 14–23, 2020, in the United States…

• 

  Dooling K, Marin M, Wallace M, McClung N, Chamberland M, Lee GM, et al. The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020 MMWR. 2021;69(5152);1657-1660.
  In Phase 1b, COVID-19 vaccine should be offered to persons aged ≥75 years and non–health care frontline essential workers, and in Phase 1c, to persons aged 65–74 years, persons aged 16–64 years with high-risk medical conditions, and essential workers not included in Phase 1b…

• 

  Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020 MMWR. 2021;69(51);1653-6.
  On December 19, 2020, after a transparent, evidence-based review of available data, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Moderna COVID-19 vaccine in persons aged ≥18 years for the prevention of COVID-19…

Top of Page